Denmark's Curasight Q2 loss narrows

Curasight A/S

27/08/2026 06:22

Overview
Danish radiopharmaceutical developer's Q2 net loss and loss per share narrowed yr/yr
Company reported encouraging preliminary Phase 1 uTREAT data in glioblastoma
Curasight raised DKK 20 mln in a directed share issue to strengthen finances

Outlook
Company expects topline Phase 1 uTREAT data in glioblastoma in H1 2027
Curasight expects Phase 2 uTRACE prostate cancer data in H1 2027
Company says timeline updates reflect uncertainty in patient enrollment

Result Drivers
GROSS LOSS - Co's gross loss reduced significantly yr/yr to DKK 9.8 mln from DKK 17.7 mln
FUNDRAISING - DKK 20 mln raised via directed share issue strengthened financial position

Company press release: ID:nWkr6GgTm7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
DKK 0.24
 
Q2 Net Loss
 
DKK 11.43 mln
 
Q2 Operating Income
 
-DKK 11.49 mln
 
Q2 Pretax Loss
 
DKK 12.80 mln
 

Reuters Recommended Reads
Aug 26 - Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Aug 26 - Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Aug 25 - Molecular Partners H1 net loss narrows on lower R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)